| Zai Lab Ltd ADR (ZLAB) | |||
|---|---|---|---|
| 16.91 0.66 (4.06%) | 05-06 16:00 | ||
| Open: | 16.85 | Pre. Close: | 16.25 |
| High: | 17.36 | Low: | 16.64 |
| Volume: | 567,858 | Market Cap: | 1,669(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 20.28 One year: 23.68 |
| Support: | Support1: 14.96 Support2: 13.48 |
| Resistance: | Resistance1: 17.36 Resistance2: 20.28 |
| Pivot: | 15.43 |
| Moving Averages: | MA(5): 16.29 MA(20): 15.32 MA(100): 20.50  MA(250): 24.65 |
| MACD: | MACD(12,26): -0.07 Signal(12,26,9): -0.42 |
| %K %D: | %K(14,3): 81.46 %D(3): 78.43 |
| RSI: | RSI(14): 58.11 |
| 52-Week: | High: 39.5 Low: 13.48 Change(%): -54.3 |
| Average Vol(K): | 3-Month: 611 10-Days: 514 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 17.373 - 17.455 | 17.455 - 17.532 |
| Low: | 16.432 - 16.526 | 16.526 - 16.613 |
| Close: | 16.757 - 16.903 | 16.903 - 17.041 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZLAB ] has closed below upper band by 10.2%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 99.21 |
| Shares Float (M) | 887.75 |
| % Held by Insiders | 1.83 |
| % Held by Institutions | 44.48 |
| Shares Short (K) | 4080 |
| Shares Short Prior Month (K) | 3660 |
| Stock Financials | |
|---|---|
| EPS | -3.500 |
| Book Value (p.s.) | 8.190 |
| Profit Margin | -125.46 |
| Operating Margin | -188.34 |
| Return on Assets (ttm) | -20.9 |
| Return on Equity (ttm) | -36.3 |
| Qtrly Rev. Growth | 5.2 |
| Gross Profit (p.s.) | |
| Sales Per Share | 2.688 |
| EBITDA (p.s.) | -3.705 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -198.18 |
| Levered Free Cash Flow (M) | -95.41 |
| Stock Valuation | |
|---|---|
| PE Ratio | -4.83 |
| PEG Ratio | 0.09 |
| Price to Book value | 2.06 |
| Price to Sales | 6.29 |
| Price to Cash Flow | -8.47 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
